185 related articles for article (PubMed ID: 31930636)
21. Industry payments and physicians prescriptions: Effect of a payment restriction policy.
Ansari B
Soc Sci Med; 2021 Jun; 278():113942. PubMed ID: 33892242
[TBL] [Abstract][Full Text] [Related]
22. Payments from drug companies to physicians are associated with higher volume and more expensive opioid analgesic prescribing.
Zezza MA; Bachhuber MA
PLoS One; 2018; 13(12):e0209383. PubMed ID: 30566426
[TBL] [Abstract][Full Text] [Related]
23. Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination.
Marcum ZA; Chang CY; Barthold D; Holmes HM; Lo-Ciganic WH
Neurol Clin Pract; 2021 Jun; 11(3):181-187. PubMed ID: 34484885
[TBL] [Abstract][Full Text] [Related]
24. Association Between Open Payments-Reported Industry Transfers of Value and Prostaglandin Analog Prescribing in the US.
Nguyen AM; Anderson KE; Anderson G; Johnson TV
JAMA Ophthalmol; 2022 Sep; 140(9):855-862. PubMed ID: 35900736
[TBL] [Abstract][Full Text] [Related]
25. Pharmaceutical opioid marketing and physician prescribing behavior.
Beilfuss S; Linde S
Health Econ; 2021 Dec; 30(12):3159-3185. PubMed ID: 34562329
[TBL] [Abstract][Full Text] [Related]
26. Industry-sponsored meal payments are associated with prescriptions and Medicare expenditures on brand-name colchicine in the United States.
Murayama A
Int J Rheum Dis; 2024 Jan; 27(1):e14962. PubMed ID: 37923570
[TBL] [Abstract][Full Text] [Related]
27. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
28. The Role of Physician Professional Networks in Physicians' Receipt of Pharmaceutical and Medical Device Industries' Payments.
Winn AN; Mitchell AP; Fergestrom N; Neuner JM; Trogdon JG
J Gen Intern Med; 2021 Jul; 36(7):1858-1866. PubMed ID: 33904046
[TBL] [Abstract][Full Text] [Related]
29. The lack of a relationship between physician payments from drug manufacturers and Medicare claims for abiraterone and enzalutamide.
Bandari J; Ayyash OM; Turner RM; Jacobs BL; Davies BJ
Cancer; 2017 Nov; 123(22):4356-4362. PubMed ID: 28749536
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
[TBL] [Abstract][Full Text] [Related]
31. Association between Opioid Prescribing in Medicare and Pharmaceutical Company Gifts by Physician Specialty.
Hollander MAG; Donohue JM; Stein BD; Krans EE; Jarlenski MP
J Gen Intern Med; 2020 Aug; 35(8):2451-2458. PubMed ID: 31792860
[TBL] [Abstract][Full Text] [Related]
32. Increasing Financial Payments From Industry to Medical Oncologists in the United States, 2014-2017.
Rahman MW; Trivedi NU; Bach PB; Mitchell AP
J Natl Compr Canc Netw; 2021 Dec; 20(13):1-9. PubMed ID: 34965511
[TBL] [Abstract][Full Text] [Related]
33. The Association of Industry Payments to Physicians with Prescription of Brand-Name Intranasal Corticosteroids.
Morse E; Fujiwara RJT; Mehra S
Otolaryngol Head Neck Surg; 2018 Sep; 159(3):442-448. PubMed ID: 29865931
[TBL] [Abstract][Full Text] [Related]
34. Medical Device Firm Payments To Physicians Exceed What Drug Companies Pay Physicians, Target Surgical Specialists.
Bergman A; Grennan M; Swanson A
Health Aff (Millwood); 2021 Apr; 40(4):603-612. PubMed ID: 33819100
[TBL] [Abstract][Full Text] [Related]
35. Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019.
Murayama A; Hoshi M; Saito H; Kamamoto S; Tanaka M; Kawashima M; Mamada H; Kusumi E; Sapkota B; Shrestha S; Shrestha R; Bhandari D; Sawano T; Yamashita E; Tanimoto T; Ozaki A
Respiration; 2022; 101(12):1088-1098. PubMed ID: 36353778
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical industry-sponsored meals are associated with increased prescriptions and Medicare spending for dupilumab among dermatologists in the United States.
Murayama A
J Eval Clin Pract; 2024 Apr; 30(3):435-439. PubMed ID: 38149692
[TBL] [Abstract][Full Text] [Related]
37. Pharmaceutical industry payments and delivery of non-recommended and low value cancer drugs: population based cohort study.
Mitchell AP; Dusetzina SB; Mishra Meza A; Trivedi NU; Bach PB; Winn AN
BMJ; 2023 Oct; 383():e075512. PubMed ID: 37879723
[TBL] [Abstract][Full Text] [Related]
38. Financial conflicts of interest between pharmaceutical companies and executive board members of internal medicine subspecialty societies in Japan between 2016 and 2020.
Murayama A; Saito H; Tanimoto T; Ozaki A
J Eval Clin Pract; 2023 Sep; 29(6):883-886. PubMed ID: 37283452
[TBL] [Abstract][Full Text] [Related]
39. Physician Payments from Pharmaceutical Companies Related to Cancer Drugs.
Mitchell AP; Mishra Meza A; Trivedi NU; Bach PB; Gönen M
Oncologist; 2022 Oct; 27(10):857-863. PubMed ID: 35946837
[TBL] [Abstract][Full Text] [Related]
40. Financial Ties Between Emergency Physicians and Industry: Insights From Open Payments Data.
Fleischman W; Ross JS; Melnick ER; Newman DH; Venkatesh AK
Ann Emerg Med; 2016 Aug; 68(2):153-158.e4. PubMed ID: 26973175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
